{"id":"stealth-liposomal-doxorubicin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Stomatitis"},{"rate":"50-70%","effect":"Hair loss"},{"rate":"1-5%","effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The liposomes help to prolong the circulation time of doxorubicin in the bloodstream, allowing it to accumulate in tumors and reduce its exposure to healthy tissues. This can lead to improved efficacy and reduced side effects compared to traditional doxorubicin formulations.","oneSentence":"Stealth liposomal doxorubicin is a formulation of doxorubicin that uses liposomes to improve its delivery and reduce its cardiotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:34.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory ovarian cancer"},{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT05567601","phase":"PHASE1","title":"Doxil/Caelyx BE Study","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2023-12-16","conditions":"Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma","enrollment":36},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT05457829","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-30","conditions":"Rhabdomyosarcoma, Child","enrollment":88},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT02098343","phase":"PHASE1, PHASE2","title":"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2014-03","conditions":"Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53","enrollment":247},{"nctId":"NCT03268382","phase":"PHASE2","title":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2017-07-31","conditions":"High-grade Serous Ovarian Cancer","enrollment":36},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT06694324","phase":"PHASE2","title":"First-line Treatment of Advanced/unresectable DDLPS","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)","enrollment":49},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00019630","phase":"PHASE1","title":"Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-07","conditions":"Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer","enrollment":""},{"nctId":"NCT00712881","phase":"PHASE2","title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Cephalon, Inc.","startDate":"2008-10-13","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT06098599","phase":"PHASE1","title":"Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2022-05-17","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT00003388","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-07-26","conditions":"Lymphoma","enrollment":38},{"nctId":"NCT02315196","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":62},{"nctId":"NCT05775705","phase":"PHASE3","title":"L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2023-08-01","conditions":"PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus","enrollment":25},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT05731258","phase":"","title":"Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Liposomal Doxorubicin, Efficacy","enrollment":150},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT00346125","phase":"NA","title":"PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-04-10","conditions":"Sarcoma","enrollment":70},{"nctId":"NCT01673217","phase":"PHASE1","title":"Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-04","conditions":"Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer","enrollment":18},{"nctId":"NCT03794778","phase":"PHASE4","title":"Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2019-03-19","conditions":"Efficacy and Safety","enrollment":396},{"nctId":"NCT05354076","phase":"PHASE2","title":"Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2000-03-01","conditions":"Advanced Malignant Tumors","enrollment":30},{"nctId":"NCT05315336","phase":"PHASE3","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2022-06-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":50},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT05273944","phase":"PHASE1","title":"Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2021-07-28","conditions":"Breast Cancer, Ovarian Cancer","enrollment":80},{"nctId":"NCT05164978","phase":"NA","title":"DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-05-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":20},{"nctId":"NCT05040555","phase":"NA","title":"R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","status":"RECRUITING","sponsor":"oubai, MD/PhD","startDate":"2021-08-30","conditions":"Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B","enrollment":64},{"nctId":"NCT04998760","phase":"PHASE2","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","status":"UNKNOWN","sponsor":"Qi Zhou","startDate":"2021-08-03","conditions":"1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer","enrollment":96},{"nctId":"NCT04983550","phase":"PHASE2","title":"Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-09","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":126},{"nctId":"NCT03055143","phase":"PHASE1","title":"Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2008-09-03","conditions":"Breast Cancer and Ovarian Cancer","enrollment":29},{"nctId":"NCT04337632","phase":"PHASE3","title":"Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2017-08-01","conditions":"Ovarian Cancer","enrollment":338},{"nctId":"NCT00296010","phase":"PHASE3","title":"Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2005-08","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT00442260","phase":"PHASE1, PHASE2","title":"Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2007-02","conditions":"Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT00101010","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT04460820","phase":"NA","title":"A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-07-04","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT01902225","phase":"PHASE1","title":"Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Weiyun Ai","startDate":"2014-03-04","conditions":"Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma","enrollment":24},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT02577783","phase":"PHASE4","title":"PDD vs PAD to Treat Initially Diagnosed MM","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":64},{"nctId":"NCT04213612","phase":"PHASE1","title":"DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-30","conditions":"Unrecognized Condition","enrollment":21},{"nctId":"NCT04023916","phase":"PHASE2","title":"Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-12-01","conditions":"Diffuse Large B-Cell Lymphoma, Sintilimab, TP53 Mutation","enrollment":30},{"nctId":"NCT03681548","phase":"PHASE1","title":"A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.","status":"COMPLETED","sponsor":"Ayana Pharma Ltd.,","startDate":"2018-08-29","conditions":"Ovarian Cancer Recurrent","enrollment":52},{"nctId":"NCT00392990","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-02-06","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT04101812","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2019-09-17","conditions":"Muscle Invasive Bladder Cancer","enrollment":60},{"nctId":"NCT00088855","phase":"PHASE2","title":"Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-06-15","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":55},{"nctId":"NCT01031420","phase":"PHASE2","title":"Dose Dense MVAC for Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2009-12-07","conditions":"Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts","enrollment":54},{"nctId":"NCT01459380","phase":"PHASE1","title":"Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-11","conditions":"Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":41},{"nctId":"NCT01281514","phase":"PHASE1","title":"A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2010-12-14","conditions":"Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":21},{"nctId":"NCT00992706","phase":"PHASE3","title":"F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2009-09","conditions":"Breast Cancer, Palmar-plantar Erythrodysesthesia","enrollment":91},{"nctId":"NCT00011986","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-01","conditions":"Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":4312},{"nctId":"NCT00761644","phase":"PHASE1","title":"Doxil, Bevacizumab and Temsirolimus Trial","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-08-21","conditions":"Advanced Cancer","enrollment":200},{"nctId":"NCT01246063","phase":"PHASE1, PHASE2","title":"Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-05-14","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT02557854","phase":"PHASE1","title":"HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors","status":"WITHDRAWN","sponsor":"Theodore Laetsch","startDate":"2016-12","conditions":"Rhabdomyosarcoma, Neuroblastoma, Sarcoma","enrollment":""},{"nctId":"NCT01489371","phase":"PHASE1","title":"EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2012-07-09","conditions":"Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":16},{"nctId":"NCT03591744","phase":"PHASE1","title":"Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2018-10-25","conditions":"Plasma Cell Leukemia","enrollment":""},{"nctId":"NCT00005991","phase":"PHASE2","title":"Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-08-25","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT00255801","phase":"PHASE2","title":"Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-11","conditions":"Lymphoma","enrollment":37},{"nctId":"NCT00074087","phase":"PHASE2","title":"Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-10","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT00389818","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-01","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT03533790","phase":"PHASE3","title":"DEP-Ru Regimen as a Salvage Therapy for HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2018-06","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":80},{"nctId":"NCT00744354","phase":"PHASE1","title":"Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2008-10","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":32},{"nctId":"NCT03387943","phase":"PHASE2","title":"PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-03-06","conditions":"Poorly Differentiated Thyroid Carcinoma","enrollment":30},{"nctId":"NCT00903630","phase":"PHASE1, PHASE2","title":"Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-04","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":15},{"nctId":"NCT01145430","phase":"PHASE1","title":"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-01","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma","enrollment":45},{"nctId":"NCT00307294","phase":"PHASE2","title":"Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-03","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT00849251","phase":"PHASE1, PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2008-11","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":31},{"nctId":"NCT00244985","phase":"PHASE1, PHASE2","title":"Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2005-09","conditions":"Lymphoma","enrollment":42},{"nctId":"NCT00331552","phase":"PHASE1, PHASE2","title":"Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-02","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":30},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00727961","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-11-09","conditions":"Ovarian Neoplasms","enrollment":58},{"nctId":"NCT02237690","phase":"PHASE1","title":"Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2014-09","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT00523848","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2006-06","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":46},{"nctId":"NCT03017404","phase":"NA","title":"A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2015-05","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT02260544","phase":"PHASE1","title":"Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2014-07","conditions":"Ovarian Epithelial Cancer Recurrent","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"stealth liposomal doxorubicin","genericName":"stealth liposomal doxorubicin","companyName":"National Cancer Institute, Naples","companyId":"national-cancer-institute-naples","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stealth liposomal doxorubicin is a formulation of doxorubicin that uses liposomes to improve its delivery and reduce its cardiotoxicity. Used for Relapsed or refractory ovarian cancer, Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}